The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update.
 
Manish Patel
Leadership - ION Pharma
Consulting or Advisory Role - Accutar Biotech; Daiichi Sankyo/UCB Japan; Kura Oncology; Mitsubishi Tanabe Pharma; Nurix; shivanka Research
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Apollo (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avenzo (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Georgiamune (Inst); Hotspot Therapeutics (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Janssen (Inst); Kineta (Inst); Kura Oncology (Inst); Kymab (Inst); Loxo (Inst); Macrogenics (Inst); Medlink (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); nurix (Inst); Olema Oncology (Inst); OnCusp Therapeutics (Inst); Pfizer (Inst); Prelude Therapeutics (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Syndax (Inst); TeneoBio (Inst); Vividion Therapeutics (Inst); Zai Lab (Inst); Zymeworks (Inst)
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Zhen Wang
No Relationships to Disclose
 
Pedro Rocha
No Relationships to Disclose
 
Qiming Wang
No Relationships to Disclose
 
Yingying Du
No Relationships to Disclose
 
Grace Dy
Consulting or Advisory Role - AADi; Amgen; AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Merus; Novartis; Regeneron
Research Funding - AMGEN (Inst); AstraZeneca (Inst); Bioatla (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Mirati Therapeutics (Inst); regeneron (Inst); Revolution Medicines (Inst); Sanofi (Inst)
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; Amgen; AstraZeneca; Tempus
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Seagen (Inst); Takeda (Inst)
 
Alex Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Xiaorong Dong
No Relationships to Disclose
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Consulting or Advisory Role - Celularity; Guardant Health; Sanofi
Speakers' Bureau - BMS; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
 
Yuping Sun
No Relationships to Disclose
 
Haiyong Wang
No Relationships to Disclose
 
Wenxiu Yao
No Relationships to Disclose
 
Luis Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Astellas Pharma (I); Crinetics Pharmaceuticals (I); Esteve (I); HUTCHMED (I); Ipsen (I); ITM Isotope Technologies Munich (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Yinjia Fu
Employment - Zai Lab
Stock and Other Ownership Interests - Zai Lab
 
Xiao Liu
Employment - Zai Lab
Stock and Other Ownership Interests - Zai Lab
 
Xiao Wang
Employment - Zai Lab
Stock and Other Ownership Interests - Zai Lab
 
Renke Zhou
Employment - Zai Lab
Stock and Other Ownership Interests - Zai Lab
 
Jun Zhao
No Relationships to Disclose